Altimmune Newsroom

JMP Securities Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $24

Futu NewsSep 11 13:32

JMP Securities Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $24

Futu NewsSep 11 05:32

Buy Rating Affirmed for Altimmune on Pemvidutide's Positive Trial Data and Strategic Advancements

TipRanksSep 11 04:37

HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target

BenzingaAug 23 01:42

Altimmune Analyst Ratings

BenzingaAug 23 01:40

H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $12

Futu NewsAug 23 00:32

Optimistic Buy Rating for Altimmune's Pemvidutide on Promising Clinical and Strategic Developments

TipRanksAug 23 00:28

Altimmune Analyst Ratings

BenzingaAug 13 02:45

B. Riley Securities Reiterates Buy on Altimmune, Maintains $20 Price Target

BenzingaAug 13 02:45

Buy Rating on Altimmune: Pemvidutide's Market Potential in Obesity and Beyond

TipRanksAug 13 00:42

Evercore ISI Remains a Buy on Altimmune (ALT)

TipRanksAug 9 21:55

Buy Rating Affirmed for Altimmune as Pemvidutide Poised to Lead NASH Treatment Market

TipRanksAug 9 06:00

B.Riley Financial Maintains Altimmune(ALT.US) With Buy Rating, Announces Target Price $20

Futu NewsAug 2 19:31

B. Riley Securities Reiterates Buy on Altimmune, Maintains $20 Price Target

BenzingaJun 25 22:04

Altimmune Analyst Ratings

BenzingaJun 22 01:52

Piper Sandler Maintains Overweight on Altimmune, Maintains $25 Price Target

BenzingaJun 22 01:52

Buy Rating Affirmed for Altimmune on Promising Pemvidutide Data and Market Position

TipRanksMay 30 14:09

Buy Rating Justified by Altimmune's Promising Pemvidutide Efficacy in NASH Treatment

TipRanksMay 22 06:10

Altimmune Analyst Ratings

BenzingaMay 14 19:55

HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target

BenzingaMay 14 19:55